おたふくかぜワクチン（MumpsVax）の世界市場レポート2025年：疫学、パイプライン分析、市場インサイトと予測

おたふくかぜワクチン（MumpsVax）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7%で29億220万米ドルに成長します。予測期間の成長は、ワクチンで予防可能な疾病の発生率の上昇、成人のワクチン接種意識の高まり、健康意識の高まり、予防接種プログラムの増加、国際的な健康イニシアチブの増加などに起因すると考えられます。予測期間の主要動向には、個別化ワクチン接種戦略、デジタルヘルス統合、モニタリングシステムの強化、成人向けワクチン接種の研究開発、人工知能の統合などがあります。

感染症の流行の高まりは、今後おたふくかぜワクチン（MumpsVax）市場の成長を促進すると予想されます。感染症は、ウイルス、細菌、真菌、寄生虫などの病原性微生物によって引き起こされる病気で、個人間または汚染された環境を通じて感染する可能性があります。都市化、気候変動、グローバリゼーション、人口動態や行動の変化などの要因が、病原体の伝播や出現の増加に寄与しています。ムンプスバックスは主に、ムンプスウイルスによって引き起こされる感染症であるおたふくかぜの予防に使用され、しばしばMMR（麻疹、おたふくかぜ、風疹）の予防接種に含まれます。例えば、2024年8月、英国健康安全保障局は、2023年にウェスト・ミッドランズ地域で最も患者数が多かった麻疹患者の増加を報告し、広範な感染症予防努力の一環としておたふくかぜワクチン接種の増加に寄与しました。したがって、感染症の増加がおたふくかぜワクチン（MumpsVax）市場を牽引しています。

ヘルスケア支出の増加がおたふくかぜワクチン（MumpsVax）市場の成長を促進すると予想されます。ヘルスケア支出とは、個人的なヘルスケア、予防サービス、健康結果の改善を目的とした公衆衛生の取り組みなど、ヘルスケア商品やサービスに費やされる総額のことです。高齢化、慢性疾患、高度医療技術、サービス需要の増加などの要因がヘルスケア支出の増加に寄与しています。このような増加は、ワクチン接種プログラムの資金を改善することでワクチンへのアクセスを向上させ、予防接種率の向上につながるため、ムンプスバックスに直接影響します。例えば、2024年5月、英国国家統計局は、2022～2023年にかけて総ヘルスケア支出が5.6%増加したことを報告し、予防接種のための資金を強化し、公衆衛生の成果を向上させました。したがって、ヘルスケア支出の増加がおたふくかぜワクチン（MumpsVax）市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のおたふくかぜワクチン（MumpsVax）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のおたふくかぜワクチン（MumpsVax）市場：成長率分析
• 世界のおたふくかぜワクチン（MumpsVax）市場の実績：規模と成長、2019～2024年
• 世界のおたふくかぜワクチン（MumpsVax）市場の予測：規模と成長、2024～2029年、2034年
• 世界のおたふくかぜワクチン（MumpsVax）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のおたふくかぜワクチン（MumpsVax）市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 一価
• 組み合わせ
• 二価
• 三価
• その他
• 世界のおたふくかぜワクチン（MumpsVax）市場：年齢層別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児
• 成人
• 世界のおたふくかぜワクチン（MumpsVax）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• ドラッグストア
• 小売薬局
• 世界のおたふくかぜワクチン（MumpsVax）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児科クリニック
• 病院
• 非政府組織（NGO）
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のおたふくかぜワクチン（MumpsVax）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のおたふくかぜワクチン（MumpsVax）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• おたふくかぜワクチン（MumpsVax）市場：競合情勢
• おたふくかぜワクチン（MumpsVax）市場：企業プロファイル
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Sinovac BIoTech Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Shaurya International

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• おたふくかぜワクチン（MumpsVax）市場、2029年：新たな機会を提供する国
• おたふくかぜワクチン（MumpsVax）市場、2029年：新たな機会を提供するセグメント
• おたふくかぜワクチン（MumpsVax）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

The mumps vaccine (MumpsVax) is a live attenuated vaccine that protects against mumps by using the Jeryl Lynn strain of the virus. It is typically administered in two doses and is commonly combined with the MMR (measles, mumps, rubella) vaccine, offering more than 95% protection against mumps. Although standalone production of the mumps vaccine has been discontinued, it continues to play a vital role in public health initiatives to control mumps outbreaks, significantly reducing the incidence of the disease in vaccinated populations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Mumps vaccine (MumpsVax) is available in several product types, including monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines specifically target mumps, while combinational vaccines provide protection against multiple diseases, such as measles and rubella, in a single shot. The vaccine is used by both pediatric and adult age groups, with distribution through hospital pharmacies, drug stores, and retail pharmacies. It is utilized by a range of end-users, including pediatric clinics, hospitals, non-governmental organizations (NGOs), and others.

The mumps vaccine (mumpsvax) market research report is one of a series of new reports from The Business Research Company that provides mumps vaccine (mumpsvax) market statistics, including mumps vaccine (mumpsvax) industry global market size, regional shares, competitors with a mumps vaccine (mumpsvax) market share, detailed mumps vaccine (mumpsvax) market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. This mumps vaccine (mumpsvax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mumps vaccine (mumpsvax) market size is expected to see strong growth in the next few years. It will grow to $2,902.2 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the rising incidence of vaccine-preventable diseases, growing adult vaccination awareness, rising health consciousness, increasing immunization programs, and increasing international health initiatives. Major trends in the forecast period include personalized vaccination strategies, digital health integration, enhanced surveillance systems, R&D for adult vaccination, and integration of artificial intelligence.

The rising prevalence of infectious diseases is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as viruses, bacteria, fungi, or parasites, which can be transmitted between individuals or through contaminated environments. Factors such as urbanization, climate change, globalization, and changes in human demographics and behavior contribute to the increased transmission and emergence of pathogens. Mumpsvax is primarily used to prevent mumps, an infectious disease caused by the mumps virus, often included in the MMR (measles, mumps, rubella) vaccination. For instance, in August 2024, the UK Health Security Agency reported a rise in measles cases, with the West Midlands region having the highest number of cases in 2023, contributing to a rise in mumps vaccinations as part of the broader infectious disease prevention efforts. Therefore, the rise in infectious diseases drives the mumps vaccine (mumpsvax) market.

Rising healthcare expenditure is expected to propel the growth of the mumps vaccine (mumpsvax) market. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal healthcare, preventive services, and public health initiatives aimed at improving health outcomes. Factors like an aging population, chronic diseases, advanced medical technology, and increasing demand for services contribute to the rise in healthcare spending. This increase directly impacts Mumpsvax by improving funding for vaccination programs, thereby boosting vaccine accessibility and leading to higher immunization rates. For instance, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, reinforcing funding for vaccinations and improving public health outcomes. Therefore, the rise in healthcare expenditure drives the mumps vaccine (mumpsvax) market.

The increasing number of clinical trials is expected to propel the growth of the mumps vaccine (mumpsvax) market. Clinical trials are essential in advancing the understanding and treatment of various health conditions, including infectious diseases like mumps. Mumpsvax serves as a reliable tool for evaluating vaccine efficacy, safety, and immune response, particularly in trials focused on pediatric immunization and viral infections. For instance, in May 2023, Xtalks reported that over 452,000 clinical trials were registered globally, a significant increase from previous years. This growing number of clinical trials contributes to the continued development and assessment of vaccines like Mumpsvax. Therefore, the increase in clinical trials drives the mumps vaccine (mumpsvax) market.

Major players operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc.; GlaxoSmithKline plc

North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mumps vaccine (mumpsvax) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mumps vaccine (mumpsvax) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mumps Vaccine (MumpsVax) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mumps vaccine (mumpsvax) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mumps vaccine (mumpsvax) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mumps vaccine (mumpsvax) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monovalent; Combinational; Divalent; Trivalent; Other Product Types
• 2) By Age Group: Pediatric; Adult
• 3) By Distribution Channels: Hospital pharmacies; Drug Stores; Retail Pharmacies
• 4) By End-User: Pediatric Clinic; Hospitals; Non-Governmental Organization (NGOs); Other End-Users
• Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mumps Vaccine (MumpsVax) Market Characteristics

3. Mumps Vaccine (MumpsVax) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Mumps Vaccine (MumpsVax) Market Trends And Strategies

5. Mumps Vaccine (MumpsVax) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Mumps Vaccine (MumpsVax) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Mumps Vaccine (MumpsVax) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Mumps Vaccine (MumpsVax) Market Growth Rate Analysis
• 6.4. Global Mumps Vaccine (MumpsVax) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Mumps Vaccine (MumpsVax) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Mumps Vaccine (MumpsVax) Total Addressable Market (TAM)

7. Global Mumps Vaccine (MumpsVax) Market Pricing Analysis & Forecasts

8. Mumps Vaccine (MumpsVax) Market Segmentation

• 8.1. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Combinational
• Divalent
• Trivalent
• Other Product Types
• 8.2. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• 8.3. Global Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Drug Stores
• Retail Pharmacies
• 8.4. Global Mumps Vaccine (MumpsVax) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Clinic
• Hospitals
• Non-Governmental Organization (NGOs)
• Other End-Users

9. Global Mumps Vaccine (MumpsVax) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Mumps Vaccine (MumpsVax) Market Regional And Country Analysis

• 10.1. Global Mumps Vaccine (MumpsVax) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Mumps Vaccine (MumpsVax) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Mumps Vaccine (MumpsVax) Market

• 11.1. Asia-Pacific Mumps Vaccine (MumpsVax) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Mumps Vaccine (MumpsVax) Market

• 12.1. China Mumps Vaccine (MumpsVax) Market Overview
• 12.2. China Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Mumps Vaccine (MumpsVax) Market

• 13.1. India Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Mumps Vaccine (MumpsVax) Market

• 14.1. Japan Mumps Vaccine (MumpsVax) Market Overview
• 14.2. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Mumps Vaccine (MumpsVax) Market

• 15.1. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Mumps Vaccine (MumpsVax) Market

• 16.1. South Korea Mumps Vaccine (MumpsVax) Market Overview
• 16.2. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Mumps Vaccine (MumpsVax) Market

• 17.1. Western Europe Mumps Vaccine (MumpsVax) Market Overview
• 17.2. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Mumps Vaccine (MumpsVax) Market

• 18.1. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Mumps Vaccine (MumpsVax) Market

• 19.1. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Mumps Vaccine (MumpsVax) Market

• 20.1. France Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mumps Vaccine (MumpsVax) Market

• 21.1. Eastern Europe Mumps Vaccine (MumpsVax) Market Overview
• 21.2. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Mumps Vaccine (MumpsVax) Market

• 22.1. North America Mumps Vaccine (MumpsVax) Market Overview
• 22.2. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Mumps Vaccine (MumpsVax) Market

• 23.1. USA Mumps Vaccine (MumpsVax) Market Overview
• 23.2. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Mumps Vaccine (MumpsVax) Market

• 24.1. Canada Mumps Vaccine (MumpsVax) Market Overview
• 24.2. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Mumps Vaccine (MumpsVax) Market

• 25.1. South America Mumps Vaccine (MumpsVax) Market Overview
• 25.2. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Mumps Vaccine (MumpsVax) Market

• 26.1. Middle East Mumps Vaccine (MumpsVax) Market Overview
• 26.2. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Mumps Vaccine (MumpsVax) Market

• 27.1. Africa Mumps Vaccine (MumpsVax) Market Overview
• 27.2. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Mumps Vaccine (MumpsVax) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Mumps Vaccine (MumpsVax) Market Competitive Landscape And Company Profiles

• 28.1. Mumps Vaccine (MumpsVax) Market Competitive Landscape
• 28.2. Mumps Vaccine (MumpsVax) Market Company Profiles
  • 28.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Sinovac Biotech Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.4. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.5. Shaurya International Overview, Products and Services, Strategy and Financial Analysis

29. Global Mumps Vaccine (MumpsVax) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Mumps Vaccine (MumpsVax) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Mumps Vaccine (MumpsVax) Market

32. Recent Developments In The Mumps Vaccine (MumpsVax) Market

33. Mumps Vaccine (MumpsVax) Market High Potential Countries, Segments and Strategies

• 33.1 Mumps Vaccine (MumpsVax) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Mumps Vaccine (MumpsVax) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Mumps Vaccine (MumpsVax) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer